Longevity: what are the biggest unsolved problems?
In our longevity market deck, you will find everything you need to understand the market
SUMMARY
The biggest unsolved problem in longevity is proving in humans that a treatment truly slows aging and extends healthy life. The field can already change parts of aging biology, but it still lacks a validated short-term measure that can stand in for decades of disease, disability and survival outcomes.
Measurement is the first bottleneck because aging clocks can predict risk without proving causality. CALERIE showed how awkward this is: one calorie-restriction intervention slowed DunedinPACE by roughly 2–3%, while other prominent methylation clocks did not show significant rejuvenation.
The newest proteomic work is encouraging because several clocks can now move in the same direction during one intervention. Even then, a younger biological-age estimate can reflect improvement in a specific disease rather than slower aging itself, so the field still has to connect biomarker change to meaningful human outcomes.
Aging also refuses to behave like one synchronized process. Large transcriptomic studies find shared mechanisms such as inflammation, senescence and metabolic dysfunction, while organ-level studies show that the brain, arteries, kidneys, reproductive tissues and other systems can age on very different timelines.
That makes causality harder than simply finding age-related changes. Senescent-cell clearance has strong causal evidence in mice, but for mitochondrial dysfunction, NAD+ metabolism, epigenetic drift, autophagy and chronic inflammation, researchers still do not know how much of total human aging each mechanism actually explains.
The most ambitious rejuvenation ideas run straight into safety limits. Partial reprogramming may reset old cellular states, yet the same growth, plasticity and cell-division programs that help regeneration can also erase cell identity or increase cancer risk if control is poor.
Precision is becoming as important as potency. Senolytics need to distinguish harmful persistent senescent cells from useful transient ones, while immune rejuvenation has to restore weakened defenses without pushing older people toward autoimmunity, chronic inflammation or weaker cancer surveillance.
The body may eventually become limited by whichever organ remains hardest to repair. Brain aging is a particularly serious candidate because many neurons are long-lived, neurodegeneration involves several interacting cell types, and the blood-brain barrier makes delivery of large molecules, gene therapies and cell-based treatments unusually difficult.
Longevity treatment will probably become a timing and combination problem. Different mechanisms interact, some therapies may conflict, and several forms of late-stage damage — lost neurons, advanced fibrosis, destroyed cartilage or large mutated clones — may be much harder to reverse than earlier metabolic or inflammatory changes.
The practical benchmark is already high. Exercise, smoking avoidance, blood-pressure control and metabolic risk management have stronger human evidence than experimental anti-aging drugs, so a real longevity breakthrough has to add healthy years beyond good preventive medicine and show biomarker change, preserved function, delayed disease and acceptable long-term safety in the same human program.
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
Can we actually tell if a longevity treatment is slowing aging without waiting decades?
Today, we still cannot reliably prove that a longevity treatment has slowed human aging rather than simply moved a biomarker associated with aging.
That is probably the most immediate bottleneck in the entire field. A drug trial cannot wait 30 years to see whether participants live longer, so researchers need measurements that respond within months or a few years. DNA-methylation clocks, blood proteins, metabolites, immune profiles and organ-specific aging models are increasingly good at predicting who is more likely to get sick or die earlier. Predicting risk, though, is easier than proving that changing the measurement changes the outcome.
The CALERIE randomized trial showed the problem clearly. Researchers assigned 220 healthy adults without obesity to calorie restriction or their normal diet for two years. The intervention group achieved roughly 12% calorie restriction on average. DunedinPACE suggested that their pace of aging slowed by about 2–3%, while PhenoAge and GrimAge showed no significant rejuvenation. One intervention therefore produced different answers depending on which biological-age clock we chose.
The field has made real progress lately. A Nature Biotechnology study published only days ago applied six different proteomic aging clocks to serum collected during a 12-week phase 2a trial of the anti-fibrotic drug rentosertib. All six clocks moved toward a younger biological-age estimate in treated patients. Agreement across six models is much more convincing than one favorable clock.
There is still a catch. The researchers could not cleanly separate a genuine effect on aging from improvement in the patients' lung disease. A clock can correctly detect that someone's biology looks healthier without telling us whether the drug changed aging itself.
That is why trial design remains so difficult. A true lifespan endpoint takes too long for most drug-development programs, while even a healthspan trial measuring dementia, cancer, cardiovascular disease and disability could require thousands of participants followed for years.
The risk of using an unvalidated shortcut is obvious: choose a clock as the target and companies will become very good at developing drugs that improve the clock.
A serious longevity trial will probably need several layers at once: molecular changes, grip strength, gait speed, cognition, organ function and actual disease events.
For now, no aging biomarker has the clinical standing of LDL cholesterol in cardiovascular medicine.
| What researchers can measure quickly | What a longevity treatment ultimately has to prove |
|---|---|
| DNA methylation | People develop major diseases later |
| Blood proteins | Disability is delayed |
| Inflammatory markers | Physical function stays intact |
| Organ-age estimates | Cognitive decline is postponed |
| Metabolites and gene expression | Healthy life actually becomes longer |
If you want more recent data on this point, please see our latest longevity market report.
Is aging one problem or dozens of different problems happening at once?
Aging currently looks more like a connected network of failures than one master process that deteriorates at the same rate everywhere.
The popular hallmarks-of-aging framework captures many of the processes involved: genomic instability, epigenetic change, loss of proteostasis, impaired autophagy, mitochondrial dysfunction, cellular senescence, altered nutrient sensing, stem-cell exhaustion, inflammation and several others. The hard part is figuring out how these pieces relate to each other.
Some evidence supports shared biology. A large cross-species analysis covering more than 11,000 transcriptomes from humans, mice, rats and macaques found recurring aging and mortality patterns involving inflammation, cellular senescence and impaired metabolism.
Human tissue data complicate the picture. Researchers examining more than 25,000 samples across 40 tissues found that organs did not deteriorate on one synchronized timetable. Vascular tissues showed relatively early changes, reproductive tissues followed very different trajectories, and several organs appeared to go through periods when deterioration accelerated.
Recent organ-aging studies make the same pattern increasingly difficult to ignore. Proteomic and imaging-based clocks can now estimate aging separately in the brain, heart, arteries, kidneys, liver, lungs, muscles and other organs. A large UK Biobank analysis of more than 43,000 people found that accelerated aging in a particular organ predicted diseases involving that organ.
Researchers increasingly need to identify which mechanisms sit high enough in the network that changing them improves several tissues at once, and which problems will need organ-specific treatment.
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Which parts of aging actually cause the damage?
Longevity research has found thousands of things that change as humans get older, but we still do not know which changes are major causes, minor contributors or simply consequences of damage happening somewhere else.
Cellular senescence is a good example. Senescent cells stop dividing and can release inflammatory molecules that disturb nearby tissue. Removing these cells improves multiple age-related conditions in mice. That gives us much stronger causal evidence than simply observing that older people have more senescent cells.
Human results remain much thinner. Senolytic drugs such as dasatinib plus quercetin have entered trials involving bone disease, cognitive decline, pulmonary disease and metabolic conditions. The SENIOR randomized osteoporosis study, for instance, was designed to test whether removing senescent cells can improve skeletal aging. We still do not have convincing evidence that senolytics broadly slow aging in humans.
The same uncertainty applies to mitochondrial dysfunction, NAD+ metabolism, epigenetic drift, autophagy and chronic inflammation. Researchers can manipulate all of them. What we cannot yet say confidently is how much total human aging each mechanism explains.
Accumulated DNA mutations add another layer. Somatic mutations build up throughout life as cells divide and experience damage. An epigenetically rejuvenated 70-year-old cell can therefore retain mutations acquired over decades.
Some changes may be reversible by resetting cell state, clearing damaged proteins or removing dysfunctional cells. Other damage may eventually require gene editing, cell replacement or selective destruction of mutated clones.
Why do longevity treatments keep working better in mice than in people?
Mouse experiments have already shown that mammalian lifespan can be extended, while human trials still have not shown that any drug makes healthy people live substantially longer.
Rapamycin captures the gap better than almost anything else. Starting rapamycin relatively late in life can extend lifespan in genetically heterogeneous mice, and the result has been reproduced across several experimental settings. Manipulating growth-hormone signaling and restricting calories can also produce large lifespan effects in laboratory animals.
Human evidence has started to become more interesting, but it is nowhere near the mouse evidence. The PEARL randomized trial followed healthy adults taking intermittent low-dose rapamycin for 48 weeks. Serious adverse events were similar across the treatment and placebo groups, while some secondary measures improved, including lean tissue mass and self-reported pain in women receiving the higher dose. Most measured outcomes did not significantly improve.
Another randomized study reported this year tested weekly rapamycin alongside exercise in 40 adults aged 65 to 85. Researchers have also reported that low-dose rapamycin reduced a marker of DNA-damage-induced senescence in immune cells from older adults. A larger National Institute on Aging-funded program has recently started testing dosing, safety and longer-term healthy-aging effects.
Species differences are only part of the problem. Laboratory mice live in controlled environments, eat standardized diets and usually have far fewer medical conditions than older humans. Humans take multiple medications, carry decades of environmental exposure and die from a much broader combination of diseases.
A 15% increase in mouse lifespan remains scientifically exciting. It still tells us very little about how many healthy years a person would gain.
If you want more recent data on this point, please see our latest longevity market report.
This chart, featured in our longevity market deck, illustrates yearly VC funding for longevity startups
Can partial reprogramming make old cells younger without causing cancer?
Partial reprogramming could become one of longevity's most powerful therapies, but today we do not know how to make old human cells younger without risking abnormal growth, lost cell identity or cancer.
The idea is unusually powerful because it suggests that a meaningful part of cellular aging may be reversible. Experiments using combinations derived from OCT4, SOX2, KLF4 and sometimes MYC have shifted old cells toward younger gene-expression and epigenetic states. Animal studies have also reported improved regeneration and function in particular tissues.
Cancer is the obvious biological constraint. Many of the processes we want to restore in old tissue — growth, cell division, plasticity and regeneration — are also processes tumors exploit.
Cellular senescence shows why the trade-off is tricky. Too many senescent cells can damage aging tissue through chronic inflammatory signaling. Yet senescence also stops damaged cells from continuing to divide. Clearing or resetting the wrong cells could interfere with tumor suppression.
Stem cells make the problem even clearer. Stem cells in blood, muscle, intestine and other tissues accumulate mutations, alter their metabolism and respond differently to inflammatory signals with age. Blood stem cells add a specific risk because clonal hematopoiesis becomes increasingly common as mutated stem-cell clones gain a competitive advantage and expand. Some of those mutations are associated with higher risks of leukemia and cardiovascular disease.
Full reprogramming can erase cell identity entirely and create pluripotent cells, bringing an obvious risk of teratomas and abnormal tissue growth. Partial reprogramming tries to stop earlier.
Turning that into a medicine requires knowing which factors should be expressed, at what dose, for how long and how frequently. Delivery may be just as difficult. Reprogramming a limited tissue such as the eye is far easier than safely reaching the brain, heart, liver, kidneys and skeletal muscle throughout an adult body.
Different tissues will probably need different settings too. A neuron that is supposed to survive for decades cannot necessarily tolerate the same treatment as a rapidly renewing intestinal cell.
We still do not have human evidence showing that partial reprogramming can make an old organ function younger for years without serious safety problems.
Can senolytic drugs kill the bad senescent cells and leave the useful ones alone?
Current senolytic drugs still cannot identify harmful senescent cells with anything close to the precision we would want from a mature therapy.
Senescence sounds like an obvious target because old organisms accumulate cells that no longer divide normally and can secrete inflammatory molecules. In mice, removing selected senescent-cell populations has improved bone, metabolic, cardiovascular and physical outcomes.
The human problem is that "senescent cell" describes a state rather than one clean cell type. Senescent cells in fat, bone, skin or the immune system can express different markers and secrete different molecules. Some are persistent and harmful. Others appear temporarily during wound healing, embryonic development and tissue repair.
A drug that kills every cell carrying one senescence-associated marker could therefore be much too crude.
Early human senolytic trials have produced biological changes but no broad clinical breakthrough. Trials of dasatinib plus quercetin, fisetin and other compounds are testing specific diseases partly because researchers can measure relevant outcomes much faster there than in a general longevity trial.
Patient selection may eventually prove just as important as drug selection. A person with a large burden of one pathological senescent-cell type might respond strongly to a treatment that does almost nothing for someone else.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Can we make an old immune system young again?
Immune rejuvenation could affect several age-related diseases at once, but making an old immune system simply "stronger" would probably create as many problems as it solves.
Older immune systems lose important capabilities. Naïve T-cell populations decline, hematopoietic stem cells change, vaccine responses weaken and immune-cell composition shifts. At the same time, many older adults show persistent low-grade inflammation associated with cardiovascular disease, metabolic dysfunction, frailty and neurodegeneration.
Recent work is showing how individual that process can be. Researchers using single-cell data from more than 1,000 healthy people between 18 and 97 built aging clocks for different immune-cell populations. Those populations did not age in exactly the same way, and infections or vaccination could temporarily move some aging signatures.
Human rapamycin research has also become more concrete lately. One placebo-controlled study found that low-dose rapamycin reduced p21, a marker linked to DNA-damage-induced senescence, in immune cells from older adults.
Stimulating immunity too aggressively could raise autoimmune or inflammatory damage. Suppressing chronic inflammation too broadly could weaken infection control and cancer surveillance.
We still do not know how to restore youthful immune balance reliably.
If you want more recent data on this point, please see our latest longevity market report.
Why can one person's brain be old while their heart is still young, and could the brain become the limit on longevity?
People increasingly appear to have several biological ages at once, and the brain may become the hardest organ to preserve if medicine extends the health of the rest of the body faster than it protects cognition.
A large proteomic study using 43,616 UK Biobank participants built aging clocks for ten organ systems and then validated them in cohorts from China and the United States. Accelerated aging of individual organs predicted later disease and mortality even after researchers accounted for conventional clinical and genetic risk factors.
Brain aging stood out because it had the strongest association with mortality. A particularly youthful brain profile also appeared to reduce Alzheimer's risk even among people carrying APOE4, one of the strongest common genetic risk factors for the disease.
Other evidence points in the same direction. Imaging-based organ clocks have found substantial differences between organ systems, while recent genetic analyses involving more than 50,000 UK Biobank participants identified 119 genetic loci associated with organ aging. Only 27 were shared across multiple organs.
The brain is especially difficult to repair. Many neurons survive for most of a person's life rather than being replaced every few days like cells in the intestine or blood. Brain aging also involves microglia, astrocytes, blood vessels, myelin, extracellular proteins and the blood-brain barrier.
Drug delivery makes the problem harder again. The blood-brain barrier blocks many molecules that reach peripheral tissues easily, while gene therapies, large proteins and cell-based treatments face particularly difficult distribution problems.
As seen above, the large proteomic analysis across three populations found that accelerated brain aging had the strongest relationship with mortality among the organ clocks they examined.
| Organ or system | What recent aging research is increasingly capturing |
|---|---|
| Brain | Dementia risk, synaptic loss, glial and vascular changes |
| Arteries | Vascular deterioration and cardiovascular risk |
| Immune system | Shifts in immune-cell populations and inflammatory activity |
| Kidney | Renal and blood-pressure-related risk |
| Muscle | Functional decline and metabolic changes |
| Liver | Metabolic resilience and liver-specific disease risk |
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Is chronic inflammation actually causing aging?
Chronic inflammation clearly drives part of age-related damage. Treating "inflammation" as one master cause, though, is too crude to produce a good longevity therapy.
Older people often develop persistent low-grade inflammatory activity known as inflammaging. Senescent cells, damaged mitochondria, visceral fat, altered gut microbes, cellular debris and immune dysfunction can all contribute.
Once inflammation rises, it can make several other problems worse. Persistent inflammatory signaling promotes insulin resistance, vascular damage, fibrosis and changes in brain immune cells. Large cross-species studies repeatedly find inflammatory pathways among the molecular patterns most closely associated with aging.
Medicine already has potent anti-inflammatory drugs. Long-term corticosteroids suppress inflammation dramatically, yet chronic use can increase infection risk, weaken bone and disrupt metabolism rather than make people younger.
The useful targets are likely to be narrower. One inflammatory pathway may be driving vascular damage, another may represent a protective response to infection, while a third may simply be reporting upstream mitochondrial or cellular damage.
Will longevity need several drugs instead of one miracle treatment?
Human aging involves enough interacting mechanisms that combination therapy currently looks more plausible than one drug fixing everything.
Rapamycin changes nutrient-sensing pathways. Senolytics try to remove dysfunctional cells. Reprogramming approaches aim to reset cellular state. Other programs target autophagy, inflammation, mitochondria, immune aging, extracellular matrix or stem cells.
Those mechanisms constantly interact. Clearing senescent cells could improve the environment in which regenerative cells operate. Better autophagy could reduce the damaged proteins and organelles that help create cellular stress. Immune rejuvenation could improve removal of abnormal cells.
Some combinations will almost certainly conflict. A therapy encouraging cell growth may pair badly with another designed to suppress proliferation. Immune activation that improves cancer surveillance could also worsen chronic inflammatory disease.
Ten candidate therapies already create 45 possible two-treatment combinations before researchers change doses, schedules or treatment order.
Timing may matter as much as drug choice.
If you want more recent data on this point, please see our latest longevity market report.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
Do longevity treatments need to start before people feel old?
Many longevity treatments will probably work better before severe damage appears, which creates an awkward mismatch between the people easiest to study and the people most likely to benefit.
Older adults with measurable disease are attractive trial participants because changes happen faster. Researchers can observe fractures, cognitive decline, disability or cardiovascular events within a realistic study period.
Prevention works on a different timeline. A therapy given to someone in their 40s or 50s might delay damage that otherwise becomes obvious decades later.
Different types of aging damage probably have different points of reversibility. Metabolic dysfunction can improve surprisingly quickly. Advanced fibrosis, lost neurons, destroyed cartilage or large mutated cell clones are much harder to reverse.
Human tissue studies also suggest that aging does not proceed at a constant rate. Some organs appear to pass through periods when structural and molecular deterioration accelerates.
We still lack validated measurements telling us exactly who is aging dangerously fast and when intervention should begin.
Why do two 70-year-olds age so differently?
People of the same chronological age can differ enormously in organ health, mobility, cognition and mortality risk, and longevity research is increasingly treating that variation as something to explain rather than average away.
Genetics clearly plays a role, but it does not explain everything. Studies of exceptionally old people repeatedly identify longevity-related variants, while behavior, environment, infections, socioeconomic conditions and ordinary preventive medicine remain powerful influences.
One study of 1,545 adults aged 80 or older compared modifiable risk factors with genetic predisposition to longevity. Participants with favorable modifiable profiles had roughly 41% lower mortality than those with unfavorable profiles. A favorable genetic score was associated with a much smaller reduction of around 13%.
Molecular data show even more variation. Longitudinal work following people over several years has found different trajectories in gene expression, metabolites and immune-cell composition.
Sex adds another layer. Menopause produces a relatively abrupt hormonal transition affecting bone, metabolism, cardiovascular risk and body composition. Men follow a different endocrine trajectory. Immune aging and the incidence of autoimmune disease, osteoporosis, cardiovascular disease and several cancers also differ substantially between women and men.
That variation can hide effective therapies. If a drug works extremely well for one biological subtype and barely works for everyone else, the average result may look disappointing.
This chart, featured in our longevity market deck, illustrates how revenue is distributed across customer segments in the longevity market
Can a longevity treatment prevent several diseases and still add healthy years?
The central promise of geroscience remains unproven in humans: no intervention has yet convincingly shown that targeting aging itself delays several major age-related diseases while preserving physical and cognitive function.
The idea is attractive for a simple reason. Cardiovascular disease, dementia, cancer, diabetes, frailty and many other conditions rise sharply with age. If several of them share upstream mechanisms, changing those mechanisms could prevent more disease than treating each condition only after it appears.
Current medicine does not make that experiment easy. Drugs are generally approved for specific diseases. Researchers can test whether a treatment prevents fractures, slows pulmonary fibrosis or delays Alzheimer's progression. "Aging" gives them no single clinical event to count.
FDA guidance already provides frameworks for multiple and composite endpoints that geroscience trials could use. Researchers are also developing hierarchical endpoints that can give greater weight to death or severe disability than to a less serious diagnosis.
Healthspan also cannot be reduced to one disease. Preventing heart attacks does not guarantee preserved memory. Delaying dementia does not prevent fractures. Improving muscle strength does not necessarily slow kidney disease.
Grip strength, gait speed, cardiorespiratory fitness and other functional measures already have decades of evidence linking them to disability and mortality. Those measurements may sometimes tell us more about meaningful longevity than a molecular clock.
Current longevity drugs have not shown that they can compress morbidity in healthy humans. Even rapamycin, one of the strongest candidates based on animal data, has so far produced relatively small and selective human effects.
Nobody has yet shown convincingly in a randomized human trial that one geroscience treatment delays several major diseases while preserving physical and cognitive function.
| Possible longevity trial endpoint | Why researchers like it | Why it still causes problems |
|---|---|---|
| All-cause mortality | Extremely hard to misinterpret | Requires very long, large trials |
| Several major diseases combined | Directly tests geroscience | Diseases differ greatly in severity |
| Disability-free survival | Closely matches healthspan | Still takes years |
| Aging biomarkers | Can move within months | No validated surrogate yet |
| Physical and cognitive function | Directly meaningful to patients | Captures only part of aging |
Are exercise and prevention still beating every longevity drug?
For someone trying to extend healthy life today, exercise, avoiding smoking, controlling blood pressure and managing metabolic risk still have much stronger human evidence than experimental anti-aging drugs.
That is an awkward benchmark for longevity biotechnology because a new drug has to beat good preventive medicine, not an empty baseline.
Exercise affects cardiovascular health, muscle, bone, insulin sensitivity and cognition. Treating hypertension and high LDL cholesterol prevents major cardiovascular events. Smoking cessation can dramatically reduce long-term disease risk. Vaccination prevents infections that become increasingly dangerous with age.
Calorie restriction gives us one of the closest direct experiments on biological aging. In CALERIE, healthy participants achieved roughly 12% average calorie restriction over two years and improved several cardiometabolic measures. DunedinPACE estimated around a 2–3% slower pace of aging, although other methylation clocks did not show significant rejuvenation.
Longevity drugs need to add something meaningful beyond those established tools. That could mean repairing damage lifestyle cannot reverse, producing benefits for people unable to exercise effectively, targeting specific aging mechanisms or extending healthspan beyond what good preventive medicine can achieve.
Rapamycin illustrates how high that bar is. The human evidence is getting more interesting these days, with randomized trials and measurable effects on immune-cell biology, but nobody can currently tell a healthy adult that taking rapamycin will add a known number of healthy years.
This chart, featured in our longevity market deck, shows how longevity plan technology has evolved over time
What are the biggest unsolved problems in longevity?
The biggest unsolved problem in longevity today is translating our growing ability to manipulate aging biology into a treatment that clearly makes humans healthier for longer.
The field has already crossed an important scientific threshold. Calorie restriction, genetics, rapamycin, senescent-cell clearance and cellular reprogramming all show that mammalian aging can be altered. Recent human studies are also producing increasingly specific biological effects rather than relying entirely on animal experiments.
Measurement remains the first major bottleneck. Aging clocks can predict disease and mortality with impressive accuracy, and the latest proteomic studies are showing better agreement across models. We still cannot confidently translate a younger clock reading into a known amount of additional healthy life.
Causality is the second. Aging involves senescence, inflammation, mitochondrial dysfunction, epigenetic changes, damaged DNA, altered nutrient sensing, stem-cell dysfunction and many other processes. We know they interact. We have a much weaker idea of which ones dominate in a particular person at a particular age.
The third problem is safety. Rejuvenation often means restoring cell division, plasticity or immune activity, while cancer and autoimmune disease exploit many of the same biological systems.
Our judgment is fairly sharp: longevity science currently has convincing proof that aging biology can be changed, but no convincing proof that a drug can broadly slow human aging and extend healthy lifespan.
The breakthrough that changes that conclusion will need to show validated biological change, preserved physical and cognitive function, delayed age-related disease and acceptable long-term safety in the same human trial.
If you want more recent data on this point, please see our latest longevity market report.
OUR METHODOLOGY
This analysis asks what the biggest unsolved problems in longevity are and turns that broad question into a set of separate problems that can be tested against evidence. We looked at measurement, causal mechanisms, translation from animals to humans, rejuvenation safety, senolytic precision, immune aging, organ-specific aging, inflammation, combination therapy, treatment timing, individual variation, healthspan endpoints and the benchmark set by existing preventive medicine.
For each dimension, we looked for the freshest and most relevant evidence available, then assessed it before forming the broader judgment. Randomized human studies, large human cohorts, registered clinical trials, tissue-level datasets and direct regulatory material received the most weight. Animal experiments were used where human studies still cannot realistically answer the question, especially around lifespan and causal manipulation.
Freshness was part of the selection process because longevity research is moving quickly. Recent proteomic, transcriptomic, single-cell and tissue studies were prioritized when they materially changed what could be said today, while older studies stayed in the analysis when they still provide the clearest foundational evidence for an important claim.
We also looked for convergence rather than building a conclusion around one unusually positive result. Agreement across several clocks, tissues, populations or study designs strengthens a claim. Disagreement is useful too: CALERIE, for example, shows why a biomarker that predicts aging risk still cannot automatically be treated as a validated surrogate for slower human aging.
We treated a problem as one of the "biggest" when it kept constraining progress across several different parts of longevity research. That is why measurement, causality, human translation and long-term safety carry more weight here than the popularity of any single molecule or company.
When the article says a treatment "slows aging," the bar is deliberately high. A molecular or biological-age change counts as evidence that something moved, but the stronger claim requires a link to preserved function, delayed disease, disability-free survival or mortality. This distinction is central to the final judgment.
Key sources used for this analysis include: Cell's framework for biomarkers of aging and longevity interventions, the CALERIE analysis of calorie restriction and DNA-methylation aging measures, the Nature Biotechnology analysis applying six proteomic aging clocks to the rentosertib phase 2a trial, Cell's expanded Hallmarks of Aging framework, the cross-species analysis of more than 11,000 mammalian transcriptomes, Nature Aging's mapping of structural aging across more than 25,000 samples and 40 tissues, Nature Medicine's histological tissue-aging clocks across 40 tissue types, the organ-specific proteomic aging-clock study in UK Biobank and external populations, the genetic analysis identifying 119 loci associated with organ aging, the causal mouse study of naturally occurring senescent-cell clearance, the SENIOR randomized trial of senolytics and skeletal aging, the late-life rapamycin lifespan study in genetically heterogeneous mice, the PEARL randomized human rapamycin trial, the RAPA-EX-01 rapamycin-and-exercise trial, the Aging Cell study of low-dose rapamycin and DNA-damage-related senescence in the human immune system, the Nature study of OSK partial reprogramming in mouse retinal tissue, the New England Journal of Medicine study of age-related clonal hematopoiesis, the single-cell immune-aging clock study across more than 1,000 people, the longitudinal multi-omics work on individual ageotypes, and the study comparing modifiable risk factors with genetic predisposition to longevity in adults aged 80 and older.
In our longevity market deck, we identify pain points entrepreneurs should prioritize
Related blog posts
- Longevity: what are the biggest challenges now?
- The most recent funding news in the longevity market
- What are the top startups in the longevity market?
- The startups that have raised the most funding in the longevity market
